DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
Why DaVita HealthCare (DVA) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Compelling Reasons to Hold on to Encompass Health Stock Right Now
by Zacks Equity Research
EHC remains well-poised for growth on the back of improved revenues, an extensive rehabilitation hospital network and sufficient cash-generating abilities.
DaVita HealthCare (DVA) Stock Moves -0.03%: What You Should Know
by Zacks Equity Research
In the latest trading session, DaVita HealthCare (DVA) closed at $159.07, marking a -0.03% move from the previous day.
Three Reasons Why You Should Hold BDX Stock in Your Portfolio Now
by Zacks Equity Research
BD's robust product portfolio and a few strategic deals raise optimism about the stock. However, stiff competition and macroeconomic volatility are concerns.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
by Zacks Equity Research
The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.
SRDX Stock Down Despite FDA Clearance for Pounce XL System
by Zacks Equity Research
Surmodics' latest regulatory achievement is likely to broaden the platform's clinical utility and significantly expand its addressable market.
5 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run lately. Stocks like THC, SLVM, DVA, NCLH and IAG are seeing price strength, and the momentum is likely to continue.
Reasons to Retain DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM continues to raise optimism among investors, owing to its strong product portfolio.
3 Buy Rated Stocks Cruising at 52 Week Highs
by Derek Lewis
Stocks making new highs tend to make even higher highs, particularly when analysts' positive earnings estimate revisions are rolling in.
Tempus Stock Up Following Collaboration Expansion in Oncology R&D
by Zacks Equity Research
TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
DaVita HealthCare (DVA) closed the most recent trading day at $163.08, moving +0.51% from the previous trading session.
Should Value Investors Buy DaVita (DVA) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.
Reasons to Retain Fresenius Medical Stock in Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of its broad dialysis product and service portfolio. Ongoing macro challenges raise concerns.
DaVita Stock Rallies 17% in 3 Months: Is it Still Worth Buying?
by Indrajit Bandyopadhyay
DVA stock has the potential to continue its uptrend on the back of better revenues per treatment as well as growth of the overall dialysis market.
Reasons to Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
VEEV Stock Down Despite Expansion of Vault QMS to Boost Patient Safety
by Zacks Equity Research
Veeva Systems' addition of new capabilities is likely to improve the timeliness and accuracy of field actions to ensure product quality and patient safety.
Reasons to Retain Intuitive Surgical Stock in Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
DaVita HealthCare (DVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $161.57, signifying a -0.01% move from its prior day's close.
Senseonics Stock Down Despite New FDA Approval for Eversense 365
by Zacks Equity Research
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice
by Zacks Equity Research
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why DaVita HealthCare (DVA) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Centene's Michigan Unit Partners With Mae to Reduce Health Disparities
by Zacks Equity Research
CNC's Meridian unit collaborates with Mae to improve health outcomes and address health disparities in Michigan.
MMSI Stock Likely to Gain From Cook Medical's Product Portfolio Buyout
by Zacks Equity Research
Merit Medical expects to solidify its foothold in the underpenetrated global lead management market via the latest asset acquisition.